FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant

Phase 1

Terminated

Conditions: Blastic Phase Chronic Myelogenous Leukemia
Childhood Chronic Myelogenous Leukemia
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Adult Acute Myeloid Leukemia
Relapsing Chronic Myelogenous Leukemia

Interventions: Biological: therapeutic allogeneic lymphocytes
Biological: aldesleukin
Other: laboratory biomarker analysis
Other: flow cytometry

First Posted Date: 2003-01-27

Last Posted Date: 2017-02-15

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00052598

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

Not Applicable

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Myelodysplastic Syndromes
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission
Acute Undifferentiated Leukemia

Interventions: Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 160

Registration Number: NCT00014235

Locations: 🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

and more 8 locations

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00005802

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Recurrent Childhood Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Childhood Acute Myeloid Leukemia in Remission

Interventions: Drug: busulfan
Drug: etoposide
Biological: aldesleukin
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2017-06-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003875

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Contiguous Stage II Small Lymphocytic Lymphoma
Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Acute Myeloid Leukemia
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Childhood Lymphoblastic Lymphoma

Interventions: Biological: alemtuzumab
Drug: fludarabine phosphate
Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: mycophenolate mofetil
Drug: cyclosporine

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00040846

Locations: 🇮🇹
University of Torino, Torino, Italy
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

and more 4 locations

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Phase 2

Completed

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Burkitt Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
de Novo Myelodysplastic Syndromes
Recurrent Grade 1 Follicular Lymphoma
Small Intestine Lymphoma
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Anaplastic Large Cell Lymphoma
Childhood Myelodysplastic Syndromes

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: tacrolimus
Drug: mycophenolate mofetil
Genetic: polymerase chain reaction
Genetic: fluorescence in situ hybridization
Genetic: polymorphism analysis
Genetic: gene expression analysis
Radiation: total-body irradiation
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2017-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 53

Registration Number: NCT00049504

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Hodgkin Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Childhood Non-Hodgkin Lymphoma
Refractory Childhood Hodgkin Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
T-Cell Chronic Lymphocytic Leukemia
T-Cell Prolymphocytic Leukemia
Recurrent Childhood Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cyclophosphamide
Drug: Cyclosporine
Drug: Cytarabine
Drug: Etoposide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Therapeutic Autologous Lymphocytes
Radiation: Total-Body Irradiation

First Posted Date: 2003-01-27

Last Posted Date: 2020-01-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 76

Registration Number: NCT00005803

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

and more 2 locations

Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

Phase 2

Conditions: Graft-vs-Host Disease

First Posted Date: 2002-03-18

Last Posted Date: 2005-06-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00032279

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 14 locations

Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis

Phase 2

Completed

Conditions: Systemic Sclerosis

First Posted Date: 2001-05-07

Last Posted Date: 2008-09-03

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00016458

Locations: 🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2001-04-11

Last Posted Date: 2005-06-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT00014755

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Colorado Cancer Center, Denver, Colorado, United States

and more 3 locations

Home Terms & Conditions Privacy Policy